Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2013
- Price to Earnings (P/E) since 2013
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Gross Profit Margin
- The gross profit margin has experienced a relatively stable trend from March 2018 through September 2023, fluctuating mostly between approximately 33% and 35%. After the data begins in March 2018 at 35.21%, there is a gradual decline reaching a low around mid-2020 near 33.44%. Subsequently, the margin demonstrates a slow recovery, stabilizing near 34.8% in the most recent quarters of 2023. This indicates consistency in managing direct production costs relative to revenue.
- Operating Profit Margin
- The operating profit margin shows a clear upward trajectory over the analyzed period. Starting at around 7.12% in early 2018, it experienced a slight dip in mid-2020 to a low near 5.55%. From that point, there is a strong and sustained increase, rising to over 12% by the end of 2022 and maintaining this level into 2023. This trend implies improved efficiency or cost control in operations, contributing to enhanced operating profitability.
- Net Profit Margin
- The net profit margin has demonstrated noticeable improvement since 2018. Initial values near 2.49% in early 2018 declined modestly to a low point during mid-2020 of approximately 1.21%, followed by a consistent improvement peaking around 8.26% by late 2022. More recently, it has slightly moderated but remains strong near 7.5% in 2023. This pattern suggests better overall profitability after expenses, taxes, and interest over the years.
- Return on Equity (ROE)
- ROE exhibits a significant positive trend from below 4% in early 2018 to over 19% by 2023. After a dip during 2020 reaching a minimum of approximately 2.36%, the ratio sharply increased in subsequent years, peaking above 22% in 2022 before a slight decline and stabilization near 19% in 2023. The upward movement shows enhanced profitability and potentially more efficient use of shareholders' equity.
- Return on Assets (ROA)
- ROA remained relatively low initially, near 1.15% in early 2018, with a decline during 2020 falling below 0.6%. It then gradually rose to nearly 4.9% by the end of 2022. This improvement continued into 2023, maintaining values above 4%. The increase indicates strengthened asset utilization in generating net income over time.
Return on Sales
Return on Investment
Gross Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Gross profit margin = 100
× (Gross profitQ3 2023
+ Gross profitQ2 2023
+ Gross profitQ1 2023
+ Gross profitQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several noteworthy trends across the examined quarters.
- Revenues
- The revenue figures demonstrate a general upward trajectory over the period from March 2018 through September 2023. Starting at approximately $2.56 billion in the first quarter of 2018, revenues increased steadily, reaching and surpassing $3.7 billion in the most recent quarters of 2023. Despite some fluctuations, particularly a dip around mid-2020 likely influenced by external factors, the overall pattern indicates consistent growth. Quarter-to-quarter variations are present but do not interrupt the long-term positive trend.
- Gross Profit
- Gross profit shows a similar growth pattern aligned with revenues. Beginning at around $911 million in March 2018, gross profit experienced fluctuations but generally increased over time, peaking at approximately $1.27 billion in the last quarter of 2021. Thereafter, gross profit remained strong, with values consistently above $1.2 billion. There is a noticeable dip in the middle of 2020, likely correlating with the decline in revenues during the same period, followed by a robust recovery.
- Gross Profit Margin
- Gross profit margin percentages, reported from the end of 2018 onward, display relative stability with slight fluctuations. Margins are mostly within the range of 33% to 35%. The margin dipped from around 35.2% in early 2019 to approximately 33.2% by the end of 2021, suggesting some pressure on cost efficiency or pricing. However, margins gradually improved from late 2021 through 2023, nearing 34.9%, indicating a modest enhancement in profitability relative to revenues.
In summary, the analyzed data reveals a company experiencing growth in both revenue and gross profit over the longer term, with some transient setbacks around mid-2020. Gross profit margins exhibit minor variability but tend to recover and improve in recent periods. This overall pattern suggests strengthening operational performance and resilience in challenging market conditions.
Operating Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Income from operations | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Income from operationsQ3 2023
+ Income from operationsQ2 2023
+ Income from operationsQ1 2023
+ Income from operationsQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals discernible trends in income from operations, revenues, and operating profit margin over the observed periods.
- Income from Operations
- Income from operations exhibited fluctuations throughout the quarters presented. Starting at 183 million USD in March 2018, it showed modest variations around the 170-210 million USD range through 2018 and 2019. A noteworthy decline occurred in June 2020 with income dropping sharply to 62 million USD, possibly reflecting an external disruption or market condition impact. Subsequent quarters showed a strong recovery and growth, surpassing previous levels, peaking at 524 million USD in September 2023 before slightly declining to 481 million USD in the final quarter observed. This pattern indicates a resilience and growth momentum following an interim setback.
- Revenues
- Revenues were generally on an upward trajectory with minor fluctuations. Values rose steadily from 2,563 million USD in March 2018 to a peak of 3,736 million USD in September 2023. Although there was a dip in mid-2020, presumably correlated with the drop in operating income, the recovery was swift, with revenues exceeding pre-decline levels by early 2021. This consistent revenue growth aligns with the company's apparent expansion and market strengthening over the period.
- Operating Profit Margin
- The operating profit margin showed a clear improving trend over the available data, starting from approximately 7.1% in early 2019 to a high of over 13% by the end of 2022. Margins increased steadily each quarter, reflecting enhanced operational efficiency or better cost management. This rising margin trend, despite fluctuations in income from operations during the pandemic period, suggests a successful adaptation to market conditions and improved profitability per unit of revenue over time.
Overall, the data indicates that while the company faced temporary challenges in mid-2020, both income from operations and revenues demonstrated significant resilience and growth. Operating efficiency improved consistently, as evidenced by the rising operating profit margins, supporting a positive operational and financial health outlook.
Net Profit Margin
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income (loss) attributable to IQVIA Holdings Inc. | ||||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income (Loss) Attributable to IQVIA Holdings Inc.
- The net income figures exhibit a generally positive trajectory over the analyzed periods. From early 2018 through 2019, net income fluctuated moderately but remained within a narrow range, with a significant dip recorded in December 2019. The year 2020 reflected pronounced volatility, including a negative figure in June followed by a recovery and rise in the following quarters. Starting in 2021, net income increased considerably, reaching peak levels in the fourth quarter of 2021. Although there is some variability in 2022 and 2023, net income stayed at relatively elevated levels compared to prior years, indicating a possible strengthening in profitability.
- Revenues
- Revenue trends display a steady increase over the period, with minor fluctuations. Between 2018 and 2019, revenues advanced gradually with slight quarter-over-quarter growth. In 2020, revenue showed a temporary dip mid-year, concurrent with the global economic environment at the time, but rebounded strongly in the second half, achieving the highest quarterly values observed in the data set. Throughout 2021 and into 2022, revenues continued to expand, reaching new highs, before maintaining elevated but more stable levels through 2023. This upward revenue trend suggests sustained business growth and market demand expansion.
- Net Profit Margin
- Net profit margin data is available beginning in the first quarter of 2019, where it started around 2.5%. Margins demonstrated a gradual upward movement through 2019 despite some quarterly variation. The most notable increase occurred starting in 2020, where margins recovered from a modest decline mid-year to a steady rise, peaking above 8% in late 2022. During 2023, profit margins remained robust, slightly dipping but stabilizing around 7.3% to 7.5%. This improvement in profit margins over time indicates enhanced operational efficiency or improved cost management alongside revenue growth.
- Summary of Observed Financial Trends
- Overall, the financial data reveals a company that has been growing its revenues consistently over the years, with net income reflecting this growth albeit with some volatility due to external or operational factors. There is clear evidence of improving profitability, as demonstrated by increasing net profit margins, which peaked in late 2022 and were maintained at healthy levels into 2023. The fluctuations in net income, especially the mid-2019 and 2020 periods, may correlate with industry-specific challenges or broader economic disruptions, yet the recovery and subsequent growth indicate resilience. The firm appears to be strengthening its financial performance in terms of both scale and efficiency.
Return on Equity (ROE)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income (loss) attributable to IQVIA Holdings Inc. | ||||||||||||||||||||||||||||||
Equity attributable to IQVIA Holdings Inc.’s stockholders | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data over the periods from March 31, 2018, to September 30, 2023, exhibits distinct trends in net income attributable to IQVIA Holdings Inc., equity attributable to stockholders, and return on equity (ROE). Each metric reveals patterns that reflect changes in the company's financial performance and equity position.
- Net Income Attributable to IQVIA Holdings Inc.
- The net income figures show variability across the quarters. Initial values in early 2018 range from 60 to 69 million US dollars, remaining relatively stable through that year. A notable decline occurs in the last quarter of 2019, dropping to 16 million US dollars, which contrasts with subsequent rises. The period of 2020 displays considerable volatility, including a negative net income in the second quarter (-23 million US dollars), followed by a recovery and growth through the end of 2020. From 2021 onward, net income demonstrates a consistent upward trend, peaking at 325 million US dollars in the first quarter of 2022 before stabilizing within the 227 to 303 million range up to the third quarter of 2023. This upward trajectory suggests improving profitability and operational performance over recent years, despite interim fluctuations.
- Equity Attributable to IQVIA Holdings Inc.’s Stockholders
- The equity attributable to stockholders generally shows a downward trend from 2018 through early 2022. Starting around 8,196 million US dollars in March 2018, equity decreases steadily, reaching its lowest at approximately 5,347 million US dollars by June 2022. After this point, a slight recovery is observed, with equity increasing moderately through 2023 to about 5,805 million US dollars in September 2023. This decline over several years may indicate share repurchases, dividend distributions, losses, or other equity-reducing events. The modest recovery towards the end of the period suggests a stabilization or reversal of prior equity reduction.
- Return on Equity (ROE)
- The ROE percentages start from the first quarter of 2019 at approximately 3.86%, remaining near this level through early 2020. A temporary dip to 2.36% occurs in the third quarter of 2020, followed by a notable and continuous increase throughout 2021 and 2022. This progression culminates in ROE values exceeding 20%, with peaks above 22% in the latter half of 2022. In 2023, ROE values moderate slightly but remain elevated around 17.78% to 19.22%, indicating enhanced efficiency in generating net income from equity. The ROE trend parallels the rising net income and declining equity base, which collectively amplify return ratios.
In summary, the company’s net income has shown significant growth after initial volatility, while equity experienced a prolonged decline with a moderate recovery in recent quarters. The return on equity improved substantially over the period analyzed, reflecting increased profitability relative to shareholder equity. These trends collectively suggest strengthening financial performance and more effective utilization of equity capital in recent years.
Return on Assets (ROA)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Net income (loss) attributable to IQVIA Holdings Inc. | ||||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data exhibits several notable trends over the examined periods, reflecting fluctuations and growth in key financial metrics.
- Net Income Attributable to IQVIA Holdings Inc. (US$ millions)
- Net income demonstrated a general upward trend from March 2018 through December 2021, rising from 69 million to a peak of 318 million. The data shows some volatility, particularly towards the end of 2019 and throughout 2020, where net income declined in the second quarter of 2020 to -23 million, indicating a loss, before rebounding strongly with consistent increases thereafter. The net income values remain robust from 2021 through the latest reported quarter in September 2023, stabilizing around the high 200s to low 300s million.
- Total Assets (US$ millions)
- Total assets remained relatively stable over the period, fluctuating modestly around the 23,000 to 26,000 million range. A slight decline is observable through parts of 2018 and 2019, followed by a gradual increase from 2020 onwards. The highest asset levels are recorded in mid-2023 at approximately 26,000 million, suggesting steady asset base growth or retention.
- Return on Assets (ROA) %
- ROA data show a pronounced improvement from 2018 into 2023. Beginning at just over 1% in 2018 and 2019, the ratio rises steadily, reaching over 4% by the end of 2022 and maintaining around that level into late 2023. This upward trend indicates improving efficiency in asset utilization to generate net income, correlating with the overall increase in net income observed. The lowest ROA values align with years where net income was more volatile or reduced, particularly in 2020.
In summary, the company exhibits strong recovery and growth in profitability following a challenging period in 2020, reflected in rising net income and ROA. Total assets show stability and slight growth, supporting operational and financial expansion.